RegMed Investors’ (RMI) Earnings: dates of releases and more results

August 16, 2022 11:38am

Upcoming Q2 earnings announcements … 34 of 35 reported so far

Added: Brainstorm Cell Therapeutics (BCLI) and Homology Medicine (FIXX)  on Monday, 8/15

Results are listed below ...

Release Results:

Ultragenyx (RARE) reported a net loss of -$158.2 M or -$2.26 per share with $706.1 M in cash

Alnylam Pharmaceuticals (ALNY) reported a net loss of -$227.4 M or -$2.29 per share with 575.5 M in cash

Sage therapeutics (SAGE) reported a net loss of -$126.3 M or -$2.13 per share with $1.13 B in cash and a "runway"  until 2025

Vericel (VCEL) reported a net loss of -$9 M or -$0.19 per share with $131M in cash and a runway to 2025.

Editas Medicine (EDIT) reported a quarterly loss of -$53.5 M or -$0.78 per share with a cash position of $527.6 m and a runway until 2024; shares have lost about 37.9% since the beginning of the year.

MiMedx (MDXG) reported a net loss of -$10.9 M or -$0.11 with $72.5 M in cash and a runway until 2024.

AxoGen (AXGN) reported a new loss of -$2.6 M or -$0.06 per share with $64.3 M in cash and a runway until 2024.

Fate Therapeutics (FATE) reported a new loss of -$76.1 m or -$0.79 per share with $580.8 M in cash and a runway until 2025

Regenxbio (RGNX) reported a net loss of -$68.2 M or -$1.58 per share with a cash position of $682 M and a runway until 2025

MiMedx (MDXG) reported a net loss of -$10.9 M or -$0.11 with $72.5 M in cash and a runway until 2024

Sage Therapeutics (SAGE) reported a net loss of -$126.3 M or -$2.13 per share with $1.3 b in cash and a runway until 2025

Intellia Therapeutics (NTLA) reported a net loss of -$100.7 M or -$1.33 per share and a cash position of $906.9 M (an ATM of -$38.9 M and a draw of -$14.3 M from employee stock plans) with a runway until 2025.

Sangamo Therapeutics (SGMO) reported a net loss of -$43.2 m or -$0.29 and a cash position of $363.7 M with a runway until 2025.

Voyager Therapeutics (VYGR) reported a new loss of -$19.1 M or -$0.50 per share and a cash position of 148.1 M with a runway until 2024.

Biostage (BSTG) reported a net loss of -$1.3 M or -0.12 per share and a cash position of $4.6M with a runway until Q2/2023 and preparing a stock reverse to execute a financing by non-U.S. Chinese investors.

bluebird bio (BLUE) reported a net loss of -$100.1 M or -$1.36 per share and a cash position of $218 M (used $8 M from a $24.7M ATM) with a runway until 2024 but, exploring alternative financing

Cellectis SA (CLLS) reporteda newt loss of -$18.9 M or -$0.36 per share and a cash position of $135 M with a runway until 2024

CRISPR Therapeutics (CRSP) reported a newt loss of -$185 M or -$2.40 per share and a cash position of $2.073.7 B with a runway until 2025

uniQure NV (QURE) reported a net loss of -$39.1 M or -0.84 per share and a cash position of $500.5 M with a runway until 1H/2025

Verastem Oncology (VSTM) reported a net loss of -$22 M or a -$0.12 per share and a cash position of $94.3 M with a runway until 2025 (with credit facility) 

Precigen (PGEN) reported a net loss of -$26.1 M or -0.13 and a cash position of $132.8 M (note: selling TransOva for $170 M to close in Q3) with a runway until 2024

Chinook Therapeutics (KDNY) reported a net loss of -$37.6 M or -0.61 per share and a cash position of $405.2 M with a runway until Q4/23

Agenus (AGEN) reported a net loss of -$49.2 M or -0.17 and a cash position of $238 M (plus $25 M in 2H/22 from Shinqrix) with a runway until 2024

Ionis Pharmaceuticals (IONS) reported a new loss of -$105 m or -0.74 per share and a cash position of $2 B with a runway until 2025

Avrobio (AVRO) reported a net loss of -$28.05 m or -0.64 per share and a cash position of $132.4 M with a runway until Q1/2024

Verve therapeutics (VERV) reported a net loss of -$40.9 m or -0.84 and a cash position of $293.6 M with a runway until 2h/25

Beam Therapeutics (BEAM) reported a new loss of -$72 M or -$1.02 per share with a cash position of $1.2 B with a runway until 2025

BioLife Solutions (BLFS) reprtedd a new loss of -$72.6 M or -$1.71 per share and a cash position of $46.6 M with a runway until 2024

Caribou Biosciences (CRBU) reported a net loss of -$26.7 M or -$0.44 per share and a cash position of $366.1 M with a runway until 2025 

Solid Biosciences (SLDB) reported a net loss of -$25.1 M or -$0.22 per share and a cash position of $169.2 M with a runway until Q2/2024

Adverum Biotechnologies (ADVM) reported a net loss of -$43.8 M or -$0.44 per share and a cash position of $235.8 M  with a runway until Q1/2024

Bellicum Pharmaceuticals (BLCM) reported a net loss of -$4 M or -0.13 per share and a cash position of $34.7 M with a runway until early 2024

Brainstorm Cell Therapeutics (BCLI) reported a net loss of -$7 M or -0.19 per share and a cash position of $12.2 M with a runway until Q4/2022

Homology Medicine (FIXX) reported a net loss of -$29.1 M or -$0.51 per share and a cash position of $225.5 M with a runway until Q4/2024

We always need a … villain and they are always multiplying – low volume as “Earnings’ season continues with a topsy-turvy share pricing which I believe will get WORSE, investors NEED to focus on LPS (loss-per-share), collaboration revenues and cash positions i.e., runways”.

T consider investment which ... CEOs are investing in their "employed" companies of which WE INVESTORS OWN; SG&A has become much too much strpping cash to unsuitable levels!!